Merck reached an agreement with Valo Health to develop a new medicine; will have help from artificial intelligence.
The race to fight against Parkinson, especially in the pharmaceutical context.
This Thursday, a multimillion-dollar agreement was announced between Merck ea Valo Health.
The Germans at Merck are a company linked to the chemical, pharmaceutical and life sciences industries; Valo Health, from the USA, is a technology company focused on developing medicines using large-scale data and computing based on artificial intelligence.
In other words, Merck makes a investment in strength and has the assistance of artificial intelligence.
In total there are 3 billion dollars, or 2.6 billion euroswhich will be paid in stages, announced Valo Health.
And there will still be extra amounts, including licensing fees and funding for research, says the .
In addition to its artificial intelligence-based research platform, Valo Health has a database with more than 17 million records of patients (anonymous).
According to the company, this allows it to optimize drug development, “so that we can move forward more quickly with the most promising candidates”.
Parkinson’s disease affects around 10 million people across the planet; In Portugal, it is estimated that there are around 20 thousand Parkinson’s patients.
The most common symptoms include muscle stiffness, slow movements and uncontrollable shaking.
